Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Cytotherapy. 2020 Mar 25;22(5):291–300. doi: 10.1016/j.jcyt.2020.01.013

Figure 1.

Figure 1.

Gating strategy to identify proportions of PBMC (a) subsets and (b) viabilities through flow cytometry. A total of 30000 singlet events was collected (top left plot). First, white blood cell (CD45+) was identified from singlets. Granulocytes (CD15+), monocytes (CD14+) and lymphocytes (CD14-CD15−) were identified from white blood cell (CD45+). B cell (CD19+), natural killer cell (CD3−CD56+), natural killer T-cell (CD3+CD56+) and T-cell (CD3+CD56−) were identified from lymphocytes. Helper T-cell (CD3+CD4+) and cytotoxic T-cell (CD3+CD8+) were identified from T-cells.